Overview

  • Product nameAnti-Tau antibodySee all Tau primary antibodies ...
  • Description
    Rabbit polyclonal to Tau
  • Tested applicationsWB, ELISA, Dot Blot, ICC/IF, IHC-FoFr, ICCmore details
  • Species reactivity
    Reacts with: Mouse, Cow, Human, Zebrafish, Apteronotus leptorhynchus
    Predicted to work with: Rat
  • Immunogen

    Synthetic peptide corresponding to human Tau surrounding Serine 262 (

    KIGSTENL

    ).

  • Positive control
    • Mouse brain tissue lysate.

Properties

Applications

Our Abpromise guarantee covers the use of ab64193 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB Use a concentration of 0.5 - 2 µg/ml. Detects a band of approximately 52 kDa (predicted molecular weight: 79 kDa).
ELISA Use a concentration of 0.1 - 1 µg/ml.
Dot Blot Use a concentration of 0.5 - 2 µg/ml. By dot blot, this antibody only recognizes the immunizing peptide.
ICC/IF Use at an assay dependent concentration.
IHC-FoFr Use at an assay dependent concentration.
ICC 1/20.
  • Application notesIs unsuitable for IHC-P.
  • Target

    • FunctionPromotes microtubule assembly and stability, and might be involved in the establishment and maintenance of neuronal polarity. The C-terminus binds axonal microtubules while the N-terminus binds neural plasma membrane components, suggesting that tau functions as a linker protein between both. Axonal polarity is predetermined by tau localization (in the neuronal cell) in the domain of the cell body defined by the centrosome. The short isoforms allow plasticity of the cytoskeleton whereas the longer isoforms may preferentially play a role in its stabilization.
    • Tissue specificityExpressed in neurons. Isoform PNS-tau is expressed in the peripheral nervous system while the others are expressed in the central nervous system.
    • Involvement in diseaseNote=In Alzheimer disease, the neuronal cytoskeleton in the brain is progressively disrupted and replaced by tangles of paired helical filaments (PHF) and straight filaments, mainly composed of hyperphosphorylated forms of TAU (PHF-TAU or AD P-TAU).
      Defects in MAPT are a cause of frontotemporal dementia (FTD) [MIM:600274]; also called frontotemporal dementia (FTD), pallido-ponto-nigral degeneration (PPND) or historically termed Pick complex. This form of frontotemporal dementia is characterized by presenile dementia with behavioral changes, deterioration of cognitive capacities and loss of memory. In some cases, parkinsonian symptoms are prominent. Neuropathological changes include frontotemporal atrophy often associated with atrophy of the basal ganglia, substantia nigra, amygdala. In most cases, protein tau deposits are found in glial cells and/or neurons.
      Defects in MAPT are a cause of Pick disease of the brain (PIDB) [MIM:172700]. It is a rare form of dementia pathologically defined by severe atrophy, neuronal loss and gliosis. It is characterized by the occurrence of tau-positive inclusions, swollen neurons (Pick cells) and argentophilic neuronal inclusions known as Pick bodies that disproportionally affect the frontal and temporal cortical regions. Clinical features include aphasia, apraxia, confusion, anomia, memory loss and personality deterioration.
      Note=Defects in MAPT are a cause of corticobasal degeneration (CBD). It is marked by extrapyramidal signs and apraxia and can be associated with memory loss. Neuropathologic features may overlap Alzheimer disease, progressive supranuclear palsy, and Parkinson disease.
      Defects in MAPT are a cause of progressive supranuclear palsy type 1 (PSNP1) [MIM:601104, 260540]; also abbreviated as PSP and also known as Steele-Richardson-Olszewski syndrome. PSNP1 is characterized by akinetic-rigid syndrome, supranuclear gaze palsy, pyramidal tract dysfunction, pseudobulbar signs and cognitive capacities deterioration. Neurofibrillary tangles and gliosis but no amyloid plaques are found in diseased brains. Most cases appear to be sporadic, with a significant association with a common haplotype including the MAPT gene and the flanking regions. Familial cases show an autosomal dominant pattern of transmission with incomplete penetrance; genetic analysis of a few cases showed the occurrence of tau mutations, including a deletion of Asn-613.
    • Sequence similaritiesContains 4 Tau/MAP repeats.
    • Developmental stageFour-repeat (type II) tau is expressed in an adult-specific manner and is not found in fetal brain, whereas three-repeat (type I) tau is found in both adult and fetal brain.
    • DomainThe tau/MAP repeat binds to tubulin. Type I isoforms contain 3 repeats while type II isoforms contain 4 repeats.
    • Post-translational
      modifications
      Phosphorylation at serine and threonine residues in S-P or T-P motifs by proline-directed protein kinases (PDPK: CDK1, CDK5, GSK-3, MAPK) (only 2-3 sites per protein in interphase, seven-fold increase in mitosis, and in PHF-tau), and at serine residues in K-X-G-S motifs by MAP/microtubule affinity-regulating kinase (MARK) in Alzheimer diseased brains. Phosphorylation decreases with age. Phosphorylation within tau's repeat domain or in flanking regions seems to reduce tau's interaction with, respectively, microtubules or plasma membrane components. Phosphorylation on Ser-610, Ser-622, Ser-641 and Ser-673 in several isoforms during mitosis.
      Polyubiquitinated. Requires functional TRAF6 and may provoke SQSTM1-dependent degradation by the proteasome (By similarity). PHF-tau can be modified by three different forms of polyubiquitination. 'Lys-48'-linked polyubiquitination is the major form, 'Lys-6'-linked and 'Lys-11'-linked polyubiquitination also occur.
      Glycation of PHF-tau, but not normal brain tau. Glycation is a non-enzymatic post-translational modification that involves a covalent linkage between a sugar and an amino group of a protein molecule forming ketoamine. Subsequent oxidation, fragmentation and/or cross-linking of ketoamine leads to the production of advanced glycation endproducts (AGES). Glycation may play a role in stabilizing PHF aggregation leading to tangle formation in AD.
    • Cellular localizationCytoplasm > cytosol. Cell membrane. Cytoplasm > cytoskeleton. Cell projection > axon. Mostly found in the axons of neurons, in the cytosol and in association with plasma membrane components.
    • Information by UniProt
    • Database links
    • FormThere are 9 isoforms produced by alternative splicing.
    • Alternative names
      • AI413597 antibody
      • AW045860 antibody
      • DDPAC antibody
      • Disinhibition dementia parkinsonism amyotrophy complex antibody
      • FLJ31424 antibody
      • FTDP 17 antibody
      • FTDP17 antibody
      • G Protein beta 1 gamma 2 subunit interacting factor 1 antibody
      • G protein beta1/gamma2 subunit interacting factor 1 antibody
      • MAPT antibody
      • MAPTL antibody
      • MGC134287 antibody
      • MGC138549 antibody
      • MGC156663 antibody
      • Microtubule associated protein tau antibody
      • Microtubule associated protein tau isoform 4 antibody
      • Microtubule-associated protein tau antibody
      • MSTD antibody
      • Mtapt antibody
      • MTBT1 antibody
      • MTBT2 antibody
      • Neurofibrillary tangle protein antibody
      • Paired helical filament tau antibody
      • Paired helical filament-tau antibody
      • PHF tau antibody
      • PHF-tau antibody
      • PPND antibody
      • pTau antibody
      • RNPTAU antibody
      • TAU antibody
      • TAU_HUMAN antibody
      • Tauopathy and respiratory failure, included antibody
      see all

    Anti-Tau antibody images

    • Immunohistochemical analysis of Apteronotus leptorhynchus brain tissue, staining Tau with ab64193.

      Tissue was fixed with paraformaldehyde, permeabilized with 0.3% Triton X-100 and blocked with 3% sheep serum (ab7489), 1% BSA and 1% teleostean gelatine in TBS for 1 hour at 24°C. Samples were incubated with primary antibody (1/20 in blocking solution) for 18 hours at 4°C. An AlexaFluor®546-conjugated goat anti-rabbit polyclonal IgG (1/200) was used as the secondary antibody.

      See Abreview

    • Immunocytochemistry of Zebrafish Cultured Cells (primary neuron), labelling Tau with ab64193.

    • Anti-Tau antibody (ab64193) at 1/100 dilution + Mouse brian whole tissue lysate at 120 µg

      Secondary
      HRP-conjugated goat anti-rabbit IgG polyclonal at 1/10000 dilution
      developed using the ECL technique

      Performed under reducing conditions.

      Predicted band size : 79 kDa
      Observed band size : 52 kDa (why is the actual band size different from the predicted?)


      Exposure time : 5 minutes

      This image is courtesy of an anonymous Abreview

      See Abreview

    • Anti-Tau antibody (ab64193) at 1/200 dilution + Mouse brain tissue lysate at 15 µg

      Predicted band size : 79 kDa
      Observed band size : 52 kDa (why is the actual band size different from the predicted?)

    References for Anti-Tau antibody (ab64193)

    This product has been referenced in:
    • Yang S  et al. Mitochondrial dysfunction driven by the LRRK2-mediated pathway is associated with loss of Purkinje cells and motor coordination deficits in diabetic rat model. Cell Death Dis 5:e1217 (2014). WB ; Rat . Read more (PubMed: 24810053) »
    • Tak H  et al. Bimolecular fluorescence complementation; lighting-up tau-tau interaction in living cells. PLoS One 8:e81682 (2013). WB ; Human . Read more (PubMed: 24312574) »

    See all 6 Publications for this product

    Product Wall

    Abreviews
    Application Western blot
    Loading amount 120 µg
    Gel Running Conditions Reduced Denaturing (15)
    Sample Mouse Tissue lysate - whole (Brain)
    Specification Brain
    Blocking step Milk as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 5% · Temperature: 25°C
    Username

    Abcam user community

    Verified customer

    Submitted Apr 16 2014

    Application Immunocytochemistry/ Immunofluorescence
    Blocking step BSA as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 5% · Temperature: 25°C
    Sample Mouse Cell (Primary neuronal cells)
    Specification Primary neuronal cells
    Permeabilization Yes - Triton-X
    Fixative Paraformaldehyde
    Username

    Abcam user community

    Verified customer

    Submitted Oct 08 2013

    Abcam guarantees this product to work in the species/application used in this Abreview.
    Application Immunohistochemistry (PFA perfusion fixed frozen sections)
    Sample Apteronotus leptorhynchus Tissue sections (Brain)
    Specification Brain
    Fixative Paraformaldehyde
    Antigen retrieval step None
    Permeabilization Yes - 0.3% Triton X-100
    Blocking step 3% sheep serum, 1% BSA, 1% teleostean gelatine in TBS as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 3% · Temperature: 24°C
    Username

    Abcam user community

    Verified customer

    Submitted Nov 26 2012

    Abcam guarantees this product to work in the species/application used in this Abreview.
    Application Western blot
    Sample Apteronotus leptorhynchus Tissue lysate - whole (Brain)
    Loading amount 50 µg
    Specification Brain
    Gel Running Conditions Reduced Denaturing (4-15%)
    Blocking step Milk as blocking agent for 14 hour(s) and 0 minute(s) · Concentration: 5% · Temperature: 4°C
    Username

    Abcam user community

    Verified customer

    Submitted Nov 26 2012

    Abreviews
    Abcam guarantees this product to work in the species/application used in this Abreview.
    Application Western blot
    Sample Mouse Cell lysate - whole cell (neuronal)
    Loading amount 30 µg
    Specification neuronal
    Gel Running Conditions Reduced Denaturing (10)
    Blocking step (agent) for 1 hour(s) and 0 minute(s) · Concentration: 100% · Temperature: 20°C
    Username

    Abcam user community

    Verified customer

    Submitted Oct 12 2012

    Thank you for your reply.


    As this product is well beyond the 6 month guarantee period, I am afraid I have no further advice. Since the antibody is almost 1 year old, it is possible that degradation could be an issue.

    Thank you for your reply.


    Can you please confirm your order number for these antibodies? Per our Abpromise, all products purchased within 6 months are eligble for replacement or credit if they do not work as stated on the datasheet. Read More

    Thank you for contacting Abcam regarding these antibodies.


    I am sorry that your customer is experiencing difficulties with these antibodies in WB. Based on the protocol information and information we have about the protein, there does n...

    Read More

    Thank you fory our enquiry.
    I am very pleased to hearthe customerwould like to make use of our testing offer and test ab64193 (Anti-Tau antibody) and ab27162 (Anti-Tau antibody [HYB338-01]) together in sandwhich ELISA in return for one free antibo...

    Read More
    Abcam has not validated the combination of species/application used in this Abreview.
    Application Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)
    Sample Mouse Tissue sections (Brain)
    Specification Brain
    Fixative Formaldehyde
    Antigen retrieval step Heat mediated - Buffer/Enzyme Used: Citric acid HIER
    Permeabilization No
    Blocking step BSA as blocking agent for 10 minute(s) · Concentration: 1% · Temperature: 21°C
    Username

    Mr. Carl Hobbs

    Verified customer

    Submitted Nov 02 2010

    Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"